Science & Technology
A novel therapeutic for Lyme arthritis based on a secretory leukocyte protease inhibitor
Department of Health and Human Services — National Institutes of Health
Opportunity #: 1R41AI186833-01
Award Ceiling
$600K
Award Floor
$600K
Close Date
Jun 30, 2026
107 days leftTotal Funding
$600K
Expected Awards
1
Posted Date
Jul 8, 2024
Cost Sharing Required
No
Grants.gov ID
sbir-1R41AI186833-01
Description
STTR Phase Phase I award: "A novel therapeutic for Lyme arthritis based on a secretory leukocyte protease inhibitor" awarded to L2 DIAGNOSTICS LLC in NEW HAVEN, Connecticut. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $599,866. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.
Eligible Applicants
Small businesses
Apply on Grants.gov
Always verify details and apply through the official Grants.gov portal. Information here may not reflect the latest changes.
View on Grants.govDisclaimer: This information is sourced from Grants.gov and may not reflect the most current details. Always verify eligibility requirements, deadlines, and application procedures on the official program website before applying.